Literature DB >> 29188995

Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside".

Paul W Manley1, Ellen Weisberg2,3, Martin Sattler2,3, James D Griffin2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29188995      PMCID： PMC6295915          DOI： 10.1021/acs.biochem.7b01126

Source DB:  PubMed          Journal:  Biochemistry        ISSN： 0006-2960            Impact factor:   3.162


× No keyword cloud information.
  5 in total

Review 1.  Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent.

Authors:  D Fabbro; E Buchdunger; J Wood; J Mestan; F Hofmann; S Ferrari; H Mett; T O'Reilly; T Meyer
Journal:  Pharmacol Ther       Date:  1999 May-Jun       Impact factor: 12.310

2.  Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

Authors:  Jason Gotlib; Hanneke C Kluin-Nelemans; Tracy I George; Cem Akin; Karl Sotlar; Olivier Hermine; Farrukh T Awan; Elizabeth Hexner; Michael J Mauro; David W Sternberg; Matthieu Villeneuve; Alice Huntsman Labed; Eric J Stanek; Karin Hartmann; Hans-Peter Horny; Peter Valent; Andreas Reiter
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

3.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Authors:  Richard M Stone; Sumithra J Mandrekar; Ben L Sanford; Kristina Laumann; Susan Geyer; Clara D Bloomfield; Christian Thiede; Thomas W Prior; Konstanze Döhner; Guido Marcucci; Francesco Lo-Coco; Rebecca B Klisovic; Andrew Wei; Jorge Sierra; Miguel A Sanz; Joseph M Brandwein; Theo de Witte; Dietger Niederwieser; Frederick R Appelbaum; Bruno C Medeiros; Martin S Tallman; Jürgen Krauter; Richard F Schlenk; Arnold Ganser; Hubert Serve; Gerhard Ehninger; Sergio Amadori; Richard A Larson; Hartmut Döhner
Journal:  N Engl J Med       Date:  2017-06-23       Impact factor: 91.245

4.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Authors:  Ellen Weisberg; Christina Boulton; Louise M Kelly; Paul Manley; Doriano Fabbro; Thomas Meyer; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

Review 5.  FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

Authors:  Ellen Weisberg; Rosemary Barrett; Qingsong Liu; Richard Stone; Nathanael Gray; James D Griffin
Journal:  Drug Resist Updat       Date:  2009-05-20       Impact factor: 18.500
  5 in total
  3 in total

1.  ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.

Authors:  Beth Apsel Winger; Wilian A Cortopassi; Diego Garrido Ruiz; Lucky Ding; Kibeom Jang; Ariel Leyte-Vidal; Na Zhang; Rosaura Esteve-Puig; Matthew P Jacobson; Neil P Shah
Journal:  Cancer Res       Date:  2019-07-03       Impact factor: 12.701

2.  Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants.

Authors:  Zheng Zhao; Lei Xie; Philip E Bourne
Journal:  J Chem Inf Model       Date:  2019-01-11       Impact factor: 4.956

3.  First Results from a Screening of 300 Naturally Occurring Compounds: 4,6-dibromo-2-(2',4'-dibromophenoxy)phenol, 4,5,6-tribromo-2-(2',4'-dibromophenoxy)phenol, and 5-epi-nakijinone Q as Substances with the Potential for Anticancer Therapy.

Authors:  Saskia Mayer; Marie Prechtl; Pia Liebfried; Ron-Patrick Cadeddu; Fabian Stuhldreier; Matthias Kohl; Folker Wenzel; Björn Stork; Sebastian Wesselborg; Peter Proksch; Ulrich Germing; Rainer Haas; Paul Jäger
Journal:  Mar Drugs       Date:  2019-09-05       Impact factor: 5.118
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.